Compare Revvity Inc (RVTY) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs T Rowe Price Group Inc — how do they compare? Revvity Inc trades at $124.14 (market cap $13.82B), while T Rowe Price Group Inc trades at $107.71 (market cap $22.98B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays the higher dividend (4.83%). Which is the better fit depends on your goals.
| RVTY | TROW | |
|---|---|---|
Market Cap | $13.82B | $22.98B |
Sector | Technology | Financials |
52-Week High | $130.94 | $121.68 |
52-Week Low | $82.26 | $86.19 |
Enterprise Value | $16.14B | $20.18B |
Dividend Yield | 0.23% | 4.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% over 24 hours, with a bullish technical signal driven by moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, supported by diagnostics growth and improved cash flow. Recent news includes the acquisition of Human Cell Design and product launches, indicating strategic expansion.
Outlook remains positive with a consensus price target of $136.20, offering ~7% upside, but high P/E of 59.54 poses valuation risk. Key opportunities include earnings momentum and innovation; risks involve premium valuation and competitive pressures in the healthcare sector.
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal and key support at $109. The stock shows strong profitability with a net margin of 29.26% and ROE of 20.1%, supported by recent earnings beats in Q1 and Q2 2026. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and ongoing AI adoption, positioning the firm for growth amid equity outflows.
The outlook is mixed: valuation metrics like a P/E of 10.99 suggest potential upside to the $111.67 consensus target, but bearish technicals and analyst caution (63% hold rating) indicate near-term headwinds. Risks include market-sensitive revenue and competitive pressures, though dividend stability and institutional buying support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
